<div id="readability-page-1"><p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as $41.05 and last traded at $40.9750, with a volume of 250063 shares trading hands. The stock had previously closed at $40.97.</p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>APLS has been the subject of several research analyst reports. Roth Mkm downgraded shares of Apellis Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, April 2nd. Citigroup  reissued a &#34;neutral&#34; rating and set a $41.00 price objective (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a &#34;neutral&#34; rating on the stock in a report on Wednesday, February 25th. HC Wainwright lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price objective for the company from $48.00 to $41.00 in a report on Wednesday, April 1st. Finally, Needham &amp; Company LLC lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, eighteen have assigned  a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Apellis Pharmaceuticals  has a consensus rating of &#34;Hold&#34; and a consensus price target of $34.89.</p><p><b>Check Out Our Latest Report on Apellis Pharmaceuticals</b></p><h2>Apellis Pharmaceuticals Stock Up 0.0%</h2><ul><li>Are Small Caps a Harbinger of Market Declines?</li></ul><p>The company's fifty day simple moving average is $29.59 and its 200-day simple moving average is $25.35. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. The firm has a market capitalization of $5.25 billion, a PE ratio of 315.29 and a beta of -0.24. </p><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. During the same period in the previous year, the company earned ($0.29) earnings per share. The business's revenue for the quarter was down 5.9% on a year-over-year basis.  On average, analysts forecast that  Apellis Pharmaceuticals, Inc. will post -1.23 EPS for the current year. </p><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2><p>Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in shares of  Apellis Pharmaceuticals by 35.9% during the fourth quarter. SG Americas Securities LLC now owns 567,046 shares of the company's stock valued at $14,244,000 after buying an additional 149,654 shares during the last quarter.  EFG Asset Management North America Corp. grew its holdings in shares of  Apellis Pharmaceuticals by 48.0% during the third quarter. EFG Asset Management North America Corp. now owns 155,399 shares of the company's stock valued at $3,517,000 after buying an additional 50,375 shares during the last quarter.  HighVista Strategies LLC grew its holdings in shares of  Apellis Pharmaceuticals by 68.2% during the third quarter. HighVista Strategies LLC now owns 145,729 shares of the company's stock valued at $3,298,000 after buying an additional 59,066 shares during the last quarter.  Readystate Asset Management LP purchased a new stake in shares of  Apellis Pharmaceuticals during the third quarter valued at $5,476,000.  Finally, Bank of Nova Scotia grew its holdings in shares of  Apellis Pharmaceuticals by 144.8% during the third quarter. Bank of Nova Scotia now owns 1,456,225 shares of the company's stock valued at $32,954,000 after buying an additional 861,413 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors. </p><h2>Apellis Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.  </p><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p><h2>See Also</h2><ul><li>Five stocks we like better than Apellis Pharmaceuticals</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

APLS

SBIO

<p>Apellis Pharmaceuticals (NASDAQ:APLS) reached a new 52-week high of $41.05, closing at $40.9750 with a trading volume of 250,063 shares. Analysts have mixed ratings, with three Buy, eighteen Hold, and two Sell ratings. The company reported $0.47 EPS, exceeding estimates, but revenue declined 5.9% year-over-year. Institutional investors hold 96.29% of shares, and Apellis focuses on therapies for rare diseases, with its lead product, Syfovre, approved for geographic atrophy.</p>

Market Beat

Apellis Pharma

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

VG Health

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

Direxion S&P Biotech Bull 3X

Beam Therapeutics

Citigroup

Bank of Nova Scottia

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High  - Here's What Happened